复发难治性弥漫大B细胞淋巴瘤二线阿基仑赛治疗的成本效益
研究基于ZUMA-7试验数据构建Markov模型,模拟美国成人原发难治/早期复发弥漫大B细胞淋巴瘤患者,比较二线阿基仑赛与标准治疗的终身成本效益,假设5年无事件生存率阿基仑赛35%、标准治疗10%时,阿基仑赛在15万美元/QALY支付意愿阈值下具有成本效益(每QALY 93 547美元),但成本效益高度依赖长期结局。
要点
- 假设5年EFS阿基仑赛35% vs 标准治疗10%,增量成本效益比为每QALY 93 547美元。
- 若阿基仑赛5年EFS≤26.4%或成本超过972 061美元,则不再具有成本效益。
- 在15万美元/QALY阈值下,10 000次蒙特卡洛模拟中73%显示阿基仑赛具有成本效益。
核心结论
- 若EFS绝对获益随时间维持,二线阿基仑赛相比标准治疗在15万美元/QALY支付意愿阈值下具有成本效益,但成本效益高度依赖长期结局。
- 常规使用二线CAR-T细胞治疗将显著增加美国医疗支出(每年超过10亿美元),即使在高危亚组中使用也是如此。
- 需要进一步降低CAR-T细胞治疗成本才能在世界许多地区可负担。
研究设计与样本
- 研究构建Markov模型(终身时间范围),模拟美国成人(平均年龄65岁)原发难治/早期复发弥漫大B细胞淋巴瘤的假设队列。
- 比较二线阿基仑赛与标准治疗(挽救性化学免疫治疗后自体干细胞移植)的成本效益,EFS和OS从ZUMA-7试验估计。
- 支付意愿阈值为每质量调整生命年15万美元。
主要发现
- 假设二线阿基仑赛5年EFS为35%、标准治疗为10%,阿基仑赛在15万美元/QALY阈值下具有成本效益,每QALY为93 547美元。
- 若阿基仑赛5年EFS≤26.4%或成本超过972 061美元,在15万美元/QALY阈值下不再具有成本效益。
- 在15万美元/QALY阈值下,10 000次蒙特卡洛迭代中73%显示二线阿基仑赛为成本效益策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ZUMA-7 (Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma) study showed that axicabtagene ciloleucel (axi-cel) improved event-free survival (EFS) compared with standard of care (SOC) salvage chemoimmunotherapy followed by autologous stem cell transplant in primary refractory/early relapsed diffuse large B-cell lymphoma (DLBCL); this led to its recent US Food and Drug Administration approval in this setting. We modeled a hypothetical cohort of US adults (mean age, 65 years) with primary refractory/early relapsed DLBCL by developing a Markov model (lifetime horizon) to model the cost-effectiveness of second-line axi-cel compared with SOC using a range of plausible long-term outcomes. EFS and OS were estimated from ZUMA-7. Outcome measures were reported in incremental cost-effectiveness ratios, with a willingness-to-pay (WTP) threshold of $150 000 per quality-adjusted life-year (QALY). Assuming a 5-year EFS of 35% with second-line axi-cel and 10% with SOC, axi-cel was cost-effective at a WTP of $150 000 per QALY ($93 547 per QALY). axi-cel was no longer cost-effective if its 5-year EFS was ≤26.4% or if it cost more than $972 061 at a WTP of $150 000. Second-line axi-cel was the cost-effective strategy in 73% of the 10 000 Monte Carlo iterations at a WTP of $150 000. If the absolute benefit in EFS is maintained over time, second-line axi-cel for aggressive relapsed/refractory DLBCL is cost-effective compared with SOC at a WTP of $150 000 per QALY. However, its cost-effectiveness is highly dependent on long-term outcomes. Routine use of second-line chimeric antigen receptor T-cell therapy would add significantly to health care expenditures in the United States (more than $1 billion each year), even when used in a high-risk subpopulation. Further reductions in the cost of chimeric antigen receptor T-cell therapy are needed to be affordable in many regions of the world.
引用
- Thiruvengadam SK, Saumoy M, Schneider Y, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022. PMID: 35914220. doi:10.1182/blood.2022016747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。